Canbridge Life Sciences Ltd., of Beijing, and Amoy Diagnostics Co. Ltd., of Xiamen, China, said they inked an agreement to develop a companion diagnostic for CAN-008. The fully human Fc fusion protein is intended to treat glioblastoma multiforme (GBM), and the company aims to begin a phase II trial in China sometime next year.